Evommune updates S-1; board elections, auditor ratified

Evommune, Inc. held its 2026 Annual Meeting of Stockholders and announced director election results and auditor ratification.

Rhea-AI Filing Summary

Evommune, Inc. held its 2026 Annual Meeting of Stockholders and announced director election results and auditor ratification. Luís Peña and Eugene Bauer, M.D. were elected to the Board with reported votes of 21,859,596 and 23,637,920 respectively. The selection of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by a vote of 24,664,299 in favor.

The prospectus supplement updates the S-1 prospectus dated April 24, 2026 and incorporates the Company’s Form 8-K filed June 2, 2026; the supplement refers readers to the Prospectus for risk disclosures. The supplement states the last reported sale price of common stock was $22.17 per share on June 1, 2026.

Insights

Corporate Governance Expert

Board slate confirmed; standard governance outcome.

The reported vote totals show that the two director nominees, Luís Peña and Eugene Bauer, M.D., were elected to terms ending at the 2029 Annual Meeting. The proxy results include broker non-votes, indicating there were shares present that abstained from voting on director elections.

Governance implications are routine: composition of the board is confirmed and no contested-election signal appears in the disclosed counts. Subsequent company filings may disclose any committee assignments or independence classifications.

Audit & Financial Reporting Expert

Independent auditor ratified by a large affirmative vote.

Stockholders ratified the selection of BDO USA, P.C. for the fiscal year ending December 31, 2026 with 24,664,299 votes for, 430 against and 29,765 abstentions. The vote reflects shareholder approval of the auditor appointment disclosed in the proxy materials.

This is a routine governance vote; any material auditor-related disclosures (fees, scope) would appear in annual filings and audit-committee disclosures in future periodic reports.

Key Figures

Prospectus supplement date: June 2, 2026 Last reported sale price: $22.17 Votes for Luís Peña: 21,859,596 votes +4 more

7 metrics

Prospectus supplement date June 2, 2026 Supplement to Prospectus dated April 24, 2026

Last reported sale price $22.17 per share on June 1, 2026

Votes for Luís Peña 21,859,596 votes Election of director (2026 Annual Meeting)

Votes for Eugene Bauer, M.D. 23,637,920 votes Election of director (2026 Annual Meeting)

Auditor ratification - For 24,664,299 votes Ratification of BDO USA, P.C. for fiscal year ending December 31, 2026

Auditor ratification - Against 430 votes Ratification vote counts

Auditor ratification - Abstain 29,765 votes Ratification vote counts

Key Terms

Prospectus Supplement, Form S-1, Form 8-K, Broker Non-Votes, +1 more

5 terms

Prospectus Supplement regulatory

"This prospectus supplement updates, amends and supplements the prospectus dated April 24, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Form S-1 regulatory

"forms a part of our Registration Statement on Form S-1 (Registration No. 333-295140)"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

Form 8-K regulatory

"information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2026"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

Broker Non-Votes financial

"Broker Non-Votes 885,750"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Independent Registered Public Accounting Firm financial

"ratify the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Offering Details

other

Offering

Offering Type other

Securities Offered common stock

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the 2026 director election results for Evommune (EVMN)?

The Company elected Luís Peña with 21,859,596 votes and Eugene Bauer, M.D. with 23,637,920 votes. The proxy also shows broker non-votes of 885,750 for the director elections.

Was the independent auditor ratified at Evommune's 2026 Annual Meeting (EVMN)?

Yes. Stockholders ratified BDO USA, P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2026 with 24,664,299 votes in favor.

Does the prospectus supplement change the April 24, 2026 S-1 for Evommune (EVMN)?

The supplement updates and supplements the S-1 prospectus dated April 24, 2026 by incorporating information from the Form 8-K filed on June 2, 2026, including the Annual Meeting vote results and related disclosures.

What was Evommune's last reported share price noted in the supplement (EVMN)?

The supplement states the last reported sale price of Evommune common stock was $22.17 per share on June 1, 2026, as reported in the document.

How many votes were recorded against or abstentions in the auditor ratification (EVMN)?

For the ratification of BDO USA, P.C., the recorded votes were 430 against and 29,765 abstaining, alongside 24,664,299 votes in favor.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:08 PM EDT Learn about SEC filing dates

Prospectus Supplement	Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated April 24, 2026)	Registration No. 333-295140

This prospectus supplement updates, amends and supplements the prospectus dated April 24, 2026 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-295140). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 2, 2026, which is set forth below.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, including and supplements and amendments thereto, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Our common stock is traded on the New York Stock Exchange under the symbol “EVMN.” On June 1, 2026, the last reported sale price of our common stock was $22.17 per share.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 5 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 2, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2026

Evommune, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-42938	85-0742575
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1891 Page Mill Road Palo Alto, CA		94304
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (925) 247-4487

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	EVMN	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 2, 2026, Evommune, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following two proposals, each of which is described in more detail in the Company’s definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission on April 21, 2026:

Proposal 1 – Election of Directors

The following nominees were elected to the Company’s Board of Directors to hold office until the Company's 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The votes cast at the Annual Meeting were as follows:

Nominee	For	Withheld	Broker Non-Votes
Luis Peña	21,859,596	1,949,148	885,750
Eugene Bauer, M.D.	23,637,920	170,824	885,750

Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm

The proposal to ratify the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes:

For	Against	Abstain	Broker Non-Votes
24,664,299	430	29,765	—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Evommune, Inc.
Date: June 2, 2026		By:	/s/ Luis Peña
			Luis Peña
			President and Chief Executive Officer